2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1124

IL37 Rescues Human OA Cartilage Explants from GAG Release
Abstract Number: 2731

Illness Perceptions and Health-Related Quality of Life in Patients with Axial Spondyloarthritis and Other Forms of Chronic Back Pain in the Spondyloarthritis Caught Early (SPACE)-Cohort
Abstract Number: 1279

Imaging of Ankylosing Spondylitis By [18f]Fluoride PET-CT to Assess Bone Formation Activity and to Monitor Anti-TNF Therapy
Abstract Number: 137

Imaging Remission By Musculoskeletal Ultrasound Leads to a Better Functional Outcome – Results of the US Impera Study – US 7-Score Implementation Study in Early Rheumatoid Arthritis
Abstract Number: 2432

Immune Abnormalities Leading to Exaggerated Production of IFN-Gamma (IFNγ) and the Therapeutic Response to an Anti-IFNγ Antibody in a Patient with NRLC4 Mediated Disease
Abstract Number: 1746

Immune Complex-Induced IL-6 Production By Lupus Prone Mesangial Cells Is Mediated By Neuraminidase Activity
Abstract Number: 1006

Immune Complex-Mediated TLR8 Activation Shifts Neutrophils from Phagocytosis to Netosis through Furin-Dependent Shedding of Fcgriia
Abstract Number: 1914

Immune Recognition of a Novel Citrullinated Epitope of Cartilage Proteoglycan Aggrecan in Mice with Proteoglycan-Induced Arthritis and in Patients with Rheumatoid Arthritis
Abstract Number: 2781

Immunization with ApoB100 Peptide Vaccine Reduces Atherosclerosis Development in a Mouse Model of Systemic Lupus Erythematosus
Abstract Number: 2814

Immunofluorescence Pattern and Titer of the Antinuclear Antibody Test Correlate with Disease Activity in Patients with Systemic Lupus Erythematosus
Abstract Number: 2610

Immunogenicity Assessment of Biologics in Clinical Studies in Chronic Inflammatory Disease: A Systematic Review
Abstract Number: 613

Immunogenicity of Anti-TNF Therapies in Patients with Inflammatory Rheumatic Diseases and Secondary Failure: A Multicentre Study of 570 Patients
Abstract Number: 1518

Immunoglobulin Binding Protein (BiP), an Antigen for CCP Sero-Positive Rheumatoid Arthritis Patients, Can Result in a False Positive Quantiferon-Gold Tuberculosis Test
Abstract Number: 666

Immunoglobulin N-Glycosylation Acquired By Somatic Hypermutation As a Potential Mechanism for Non-Specific B Cell Activation in Sjogren’s Syndrome
Abstract Number: 2844

Immunoglobulins Level and Risk of Infection in Systemic Lupus Erythematosus

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].